Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A southwest oncology group study

Phase II study of platinum and mitoxantrone in metastatic prostate cancer: a Southwest Oncology Group Study

European Journal of Cancer ◽

10.1016/s0959-8049(05)80080-2 ◽

1992 ◽

Vol 28 (2-3) ◽

pp. 477-478 ◽

Cited By ~ 17

Author(s):

C.K. Osborne ◽

G.R. Weiss ◽

B.A. Blumenstein ◽

E.D. Crawford ◽

R.M. Bukowski ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Metastatic Prostate Cancer ◽

Phase Ii Study ◽

Oncology Group ◽

Oncology Group Study ◽

PROGNOSTIC VALUE OF ANEMIA IN NEWLY DIAGNOSED METASTATIC PROSTATE CANCER: A MULTIVARIATE ANALYSIS OF SOUTHWEST ONCOLOGY GROUP STUDY 8894

The Journal of Urology ◽

10.1097/01.ju.0000147771.92104.83 ◽

2004 ◽

Vol 172 (6 Part 1) ◽

pp. 2213-2217 ◽

Cited By ~ 17

Author(s):

TOMASZ M. BEER ◽

CATHERINE M. TANGEN ◽

LISA B. BLAND ◽

IAN M. THOMPSON ◽

E. DAVID CRAWFORD

Keyword(s):

Prostate Cancer ◽

Multivariate Analysis ◽

Prognostic Value ◽

Metastatic Prostate Cancer ◽

Newly Diagnosed ◽

Oncology Group ◽

Oncology Group Study ◽

Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111)

10.1200/jco.2004.22.90140.4510 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4510-4510 ◽

Cited By ~ 4

Author(s):

M. Hussain ◽

J. Faulkner ◽

U. Vaishampayan ◽

P. Lara ◽

D. Petrylak ◽

...

Keyword(s):

Prostate Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Epothilone B ◽

Ten-year Follow-up of Neoadjuvant Therapy with Goserelin Acetate and Flutamide Before Radical Prostatectomy for Clinical T3 and T4 Prostate Cancer: Update on Southwest Oncology Group Study 9109

Urology ◽

10.1016/j.urology.2011.11.019 ◽

2012 ◽

Vol 79 (3) ◽

pp. 633-637 ◽

Cited By ~ 24

Author(s):

Ryan K. Berglund ◽

Catherine M. Tangen ◽

Isaac J. Powell ◽

Bruce A. Lowe ◽

Gabriel P. Haas ◽

...

Keyword(s):

Prostate Cancer ◽

Radical Prostatectomy ◽

Neoadjuvant Therapy ◽

Oncology Group ◽

Oncology Group Study ◽

Goserelin Acetate

Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916

10.1200/jco.2004.22.14_suppl.4505 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4505-4505 ◽

Cited By ~ 3

Author(s):

E. D. Crawford ◽

D. K. Pauler ◽

C. M. Tangen ◽

M. H. A. Hussain ◽

E. J. Small ◽

...

Keyword(s):

Prostate Cancer ◽

Surrogate Endpoint ◽

Oncology Group ◽

Oncology Group Study ◽

Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916

10.1200/jco.2004.22.90140.4505 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4505-4505

Author(s):

E. D. Crawford ◽

D. K. Pauler ◽

C. M. Tangen ◽

M. H. A. Hussain ◽

E. J. Small ◽

...

Keyword(s):

Prostate Cancer ◽

Surrogate Endpoint ◽

Oncology Group ◽

Oncology Group Study ◽

Locally Advanced Prostate Cancer Treated With Concomitant Radiation and 5-Fluorouracil: Southwest Oncology Group Study 9024

The Journal of Urology ◽

10.1016/j.juro.2006.03.068 ◽

2006 ◽

Vol 176 (2) ◽

pp. 548-553 ◽

Cited By ~ 7

Author(s):

Gregory P. Swanson ◽

James Faulkner ◽

Stephen R. Smalley ◽

Mark J. Noble ◽

Ronald L. Stephens ◽

...

Keyword(s):

Prostate Cancer ◽

Advanced Prostate Cancer ◽

Locally Advanced ◽

Oncology Group ◽

Locally Advanced Prostate Cancer ◽

Oncology Group Study ◽

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235)

Urology ◽

10.1016/s0090-4295(01)01010-x ◽

2001 ◽

Vol 58 (1) ◽

pp. 53-58 ◽

Cited By ~ 77

Author(s):

Omer Kucuk ◽

Emily Fisher ◽

Carol M Moinpour ◽

Dorothy Coleman ◽

Maha H.A Hussain ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Hormonal Therapy ◽

Advanced Prostate Cancer ◽

Phase Ii Trial ◽

Oncology Group ◽

Oncology Group Study ◽

Epothilone B (Epo-B) analogue BMS-247550 (NSC #710428) administered every 21 days in patients (pts) with hormone refractory prostate cancer (HRPC). A Southwest Oncology Group Study (S0111)

10.1200/jco.2004.22.14_suppl.4510 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4510-4510 ◽

Cited By ~ 6

Author(s):

M. Hussain ◽

J. Faulkner ◽

U. Vaishampayan ◽

P. Lara ◽

D. Petrylak ◽

...

Keyword(s):

Prostate Cancer ◽

Oncology Group ◽

Oncology Group Study ◽

Epothilone B ◽

SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: A southwest oncology group study

The Prostate ◽

10.1002/pros.10118 ◽

2002 ◽

Vol 52 (4) ◽

pp. 264-268 ◽

Cited By ~ 8

Author(s):

Catherine E. Klein ◽

Catherine M. Tangen ◽

Thomas J. Braun ◽

Maha H.A. Hussain ◽

David M. Peereboom ◽

...

Keyword(s):

Prostate Cancer ◽

Oncology Group ◽

Oncology Group Study ◽